Information Disclosure and Competitive Dynamics: Evidence from the Pharmaceutical Industry

References

• ACMA (2023) What you should know about the weight loss product competition. Accessed January 8, 2024, https://medicalaffairsspecialist.org/blog/weight-loss-meds-ozempic-mounjaro.Google Scholar
• Aghamolla C, Thakor RT (2022) Do mandatory disclosure requirements for private firms increase the propensity of going public? J. Accounting Res. 60(3):755–804.Crossref, Google Scholar
• Aghion P, Bloom N, Blundell R, Griffith R, Howitt P (2005) Competition and innovation: An inverted-U relationship. Quart. J. Econom. 120(2):701–728.Google Scholar
• Allain M-L, Henry E, Kyle M (2016) Competition and the efficiency of markets for technology. Management Sci. 62(4):1000–1019.Link, Google Scholar
• Anderson ML, Chiswell K, Peterson ED, Tasneen A, Topping J, Califf RM (2015) Compliance with results reporting at ClinicalTrials.gov. New England J. Medicine 372(11):1031–1039.Crossref, Google Scholar
• Anton JJ, Yao DA (1994) Expropriation and inventions: Appropriable rents in the absence of property rights. Amer. Econom. Rev. 84(1):190–209.Google Scholar
• Arora A, Fosfuri A, Gambardella A (2004) Markets for Technology: The Economics of Innovation and Corporate Strategy (MIT Press, Cambridge, MA).Google Scholar
• Arora A, Gambardella A, Magazzini L, Pammolli F (2009) A breath of fresh air? Firm type, scale, scope, and selection effects in drug development. Management Sci. 55(10):1638–1653.Link, Google Scholar
• Arrow K (1963) Uncertainty and the welfare economics of medical care. Amer. Econom. Rev. 53(5):941–973.Google Scholar
• Arrow KJ (1972) Economic welfare and the allocation of resources for invention. Rowley CK, ed. Readings in Industrial Economics (Palgrave, London), 219–236.Crossref, Google Scholar
• Aryal G, Ciliberto F, Farmer LE, Khmelnitskaya E (2023) Valuing Pharmaceutical Drug Innovations (Social Science Research Network, Rochester, NY).Google Scholar
• Azoulay P (2002) Do pharmaceutical sales respond to scientific evidence. J. Econom. Management Strategy 11(4):551–594.Crossref, Google Scholar
• Azoulay P, Graff Zivin JS, Wang J (2010) Superstar extinction. Quart. J. Econom. 125(2):549–589.Crossref, Google Scholar
• Azoulay P, Greenblatt WH, Heggeness ML (2021) Long-term effects from early exposure to research: Evidence from the NIH “yellow berets.” Res. Policy 50(9):104332.Crossref, Google Scholar
• Berenson A (2005) Despite vow, drug makers still withhold data. New York Times (May 31), https://www.nytimes.com/2005/05/31/business/despite-vow-drug-makers-still-withhold-data.html.Google Scholar
• Bloom N, Schankerman MS, Van Reenen J (2013) Identifying technology spillovers and product market rivalry. Econometrica 81(4):1347–1393.Crossref, Google Scholar
• Bloom N, Propper C, Seiler S, Van Reenen J (2015) The impact of competition on management quality: Evidence from public hospitals. Rev. Econom. Stud. 82(2):457–489.Crossref, Google Scholar
• Board O (2009) Competition and disclosure. J. Indust. Econom. 57(1):197–213.Crossref, Google Scholar
• Borusyak K, Jaravel X, Spiess J (2024) Revisiting event-study designs: Robust and efficient estimation. Rev. Econom. Stud. Forthcoming.Google Scholar
• Bourgeois F, Murthy S, Mandl K (2010) Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann. Internal Medicine 153(3):158–166.Crossref, Google Scholar
• Budish E, Roin B, Williams H (2015) Do firms underinvest in long-term research? Evidence from cancer clinical trials. Amer. Econom. Rev. 105(7):2044–2085.Crossref, Google Scholar
• Callaway B, Sant’Anna PH (2021) Difference-in-differences with multiple time periods. J. Econometrics 225(2):200–230.Crossref, Google Scholar
• Celgene (2024) Data sharing request process. Accessed February 10, 2024, https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/.Google Scholar
• Chan T, Nickerson JA, Owan H (2007) Strategic management of R&D pipelines with cospecialized investments and technology markets. Management Sci. 53(4):667–682.Link, Google Scholar
• Clinical Trials Transformation Initiative (2024) Improving public access to aggregate content of ClinicalTrials.gov. Accessed April 25, 2022, https://aact.ctti-clinicaltrials.org/.Google Scholar
• Cockburn IM, Henderson RM, Stern S (2000) Untangling the origins of competitive advantage. Strategic Management J. 21(10–11):1123–1145.Crossref, Google Scholar
• Cohen WM, Levinthal DA (1990) Absorptive capacity: A new perspective on learning and innovation. Admin. Sci. Quart. 35(1):128–152.Crossref, Google Scholar
• Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, Pangalos MN (2014) Lessons learned from the fate of AstraZeneca’s drug pipeline: A five-dimensional framework. Nature Rev. Drug Discovery 13(6):419–431.Crossref, Google Scholar
• Cookson JA (2018) Anticipated entry and entry deterrence: Evidence from the American casino industry. Management Sci. 64(5):2325–2344.Link, Google Scholar
• Cunningham C, Ederer F, Ma S (2021) Killer acquisitions. J. Political Econom. 129(3):649–702.Crossref, Google Scholar
• Dabrowska A, Thaul S (2018) How FDA Approves Drugs and Regulates Their Safety and Effectiveness (Congressional Research Service, Washington, DC), 1–25.Google Scholar
• Darrow J, Kesselheim AS (2018) Promoting competition to address pharmaceutical prices. Health Affairs (March 15), https://www.healthaffairs.org/content/briefs/promoting-competition-address-pharmaceutical-prices.Google Scholar
• David PA, Hall BH, Toole AA (2000) Is public R&D a complement or substitute for private R&D? A review of the econometric evidence. Res. Policy 29(4–5):497–529.Crossref, Google Scholar
• Davis P (2006) Measuring the business stealing, cannibalization and market expansion effects of entry in the US motion picture exhibition market. J. Indust. Econom. 54(3):293–321.Crossref, Google Scholar
• de Chaisemartin C, D’Haultfoeuille X (2020) Two-way fixed effects estimators with heterogeneous effects. Amer. Econom. Rev. 110(9):2964–2996.Crossref, Google Scholar
• Department of Health and Human Services (2014) Guidance for industry expedited programs for serious conditions—Drugs and biologics. Accessed October 8, 2024, https://www.fda.gov/media/86377/download.Google Scholar
• Department of Health and Human Services (2016) Clinical trials registration and results information submission; final rule (42 CFR Part 11) information. Accessed October 8, 2024, https://www.ecfr.gov/current/title-42/chapter-I/subchapter-A/part-11.Google Scholar
• Dranove D, Jin GZ (2010) Quality disclosure and certification: Theory and practice. J. Econom. Literature 48(4):953–963.Crossref, Google Scholar
• Dyer O (2020) What did we learn from Tamiflu? BMJ 368:m626.Crossref, Google Scholar
• Eichler H-G, Petavy F, Pignatti F, Rasi G (2013) Access to patient-level trial data—A boon to drug developers. New England J. Medicine 369(17):1577–1579.Crossref, Google Scholar
• Ellison G, Ellison SF (2011) Strategic entry deterrence and the behavior of pharmaceutical incumbents prior to patent expiration. Amer. Econom. J. Microeconomics 3(1):1–36.Crossref, Google Scholar
• Gans J, Stern S (2003) The product market and the market for “ideas”: Commercialization strategies for technology entrepreneurs. Res. Policy 32(2):333–350.Crossref, Google Scholar
• Gans JS, Hsu DH, Stern S (2008) The impact of uncertain intellectual property rights on the market for ideas: Evidence from patent grant delays. Management Sci. 54(5):982–997.Link, Google Scholar
• Gardner J (2023) Novo obesity drug protects heart health in large trial. Accessed January 8, 2024, https://www.biopharmadive.com/news/novo-nordisk-wegovy-obesity-heart-cardiovascular-select-protect/690195/.Google Scholar
• Garfinkel J, Hammoudeh M (2024) Competition and innovation revisited: A product-level view. Rev. Financial Stud. Forthcoming.Google Scholar
• Gaynor M (2011) What do we know about competition and quality in healthcare markets? Foundations Trends Microeconomics 2:441–508.Crossref, Google Scholar
• Gelijns AC, Rosenberg N, Moskowitz A (1998) Capturing the unexpected benefits of medical research. New England J. Medicine 339(10):693–698.Crossref, Google Scholar
• Gentzkow M, Kamenica E (2017) Competition in persuasion. Rev. Econom. Stud. 84(1):300–322.Crossref, Google Scholar
• Gilchrist D (2016) Patents as a spur to subsequent innovation? Evidence from pharmaceuticals. Amer. Econom. J. Appl. Econom. 8(4):189–221.Crossref, Google Scholar
• Goetz CF, Shapiro AH (2012) Strategic alliance as a response to the threat of entry: Evidence from airline codesharing. Internat. J. Indust. Organ. 30(6):735–747.Crossref, Google Scholar
• Goodman-Bacon A (2021) Difference-in-differences with variation in treatment timing. J. Econometrics 225(2):254–277.Crossref, Google Scholar
• Goolsbee A, Syverson C (2008) How do incumbents respond to the threat of entry? Evidence from the major airlines. Quart. J. Econom. 123(4):1611–1633.Crossref, Google Scholar
• Grossman S (1981) The informational role of warranties and private disclosure about product quality. J. Law Econom. 24(3):461–489.Crossref, Google Scholar
• Grossman S, Hart OD (1980) Disclosure laws and takeover bids. J. Finance 35(2):323–334.Crossref, Google Scholar
• Guedj I, Scharfstein DS (2004) Organizational scope and investment: Evidence from the drug development strategies and performance of biopharmaceutical firms. Working Paper No. 10933, National Bureau of Economic Research, Cambridge, MA.Google Scholar
• Guo L, Zhao Y (2009) Voluntary quality disclosure and market interaction. Marketing Sci. 28(3):488–501.Link, Google Scholar
• Harris G (2010) Diabetes drug maker hid test data, files indicate. New York Times (July 13), https://www.nytimes.com/2010/07/13/health/policy/13avandia.html.Google Scholar
• Healy PM, Palepu KG (2001) Information asymmetry, corporate disclosure, and the capital markets: A review of the empirical disclosure literature. J. Accounting Econom. 31(1):405–440.Crossref, Google Scholar
• Hegde D, Luo H (2018) Patent publication and the market for ideas. Management Sci. 64(2):652–672.Link, Google Scholar
• Hermosilla M (2021) Rushed innovation: Evidence from drug licensing. Management Sci. 67(1):257–278.Link, Google Scholar
• Hsu P-H, Lee K, Moon SK, Oh S (2024) Information disclosure and peer innovation: Evidence from mandatory reporting of clinical trials. Working paper, Social Science Research Network, Rochester, NY.Google Scholar
• Hudson K, Lauer M, Collins F (2016) Toward a new era of trust and transparency in clinical trials. J. Amer. Medical Assoc. 316(13):1353–1354.Crossref, Google Scholar
• Ioannidis J (2005) Why most published research findings are false. PLoS Medicine 2(8):e124.Crossref, Google Scholar
• Jansen J (2010) Strategic information disclosure and competition for an imperfectly protected innovation. J. Indust. Econom. 58(2):349–372.Crossref, Google Scholar
• Jansen J (2017) A note on quality disclosure and competition. J. Indust. Econom. 65(4):833–841.Crossref, Google Scholar
• Jin GZ (2005) Competition and disclosure incentives: An empirical study of HMOs. RAND J. Econom. 36(1):93–112.Google Scholar
• Jin GZ, Luca M, Martin D (2021) Is no news (perceived as) bad news? An experimental investigation of information disclosure. Amer. Econom. J. Microeconomics 13(2):141–173.Crossref, Google Scholar
• Jovanovic B (1982) Truthful disclosure of information. Bell J. Econom. 13(1):36–44.Crossref, Google Scholar
• Kao J, Ross JS, Miller JE (2023) Transparency of results reporting in cancer clinical trials. JAMA Network Open 6(8):e2328117.Crossref, Google Scholar
• Kessler DA, Rose JL, Temple RJ, Schapiro R, Griffin JP (1994) Therapeutic-class wars—Drug promotion in a competitive marketplace. New England J. Medicine 331(20):1350–1353.Crossref, Google Scholar
• Koning R, Samila S, Ferguson J-P (2020) Inventor gender and the direction of invention. AEA Papers Proc., vol. 110 (American Economic Association, Nashville, TN), 250–254.Google Scholar
• Krieger JL (2021) Trials and terminations: Learning from competitors’ R&D failures. Management Sci. 67(9):5525–5548.Link, Google Scholar
• Krieger J, Li D, Papanikolaou D (2022a) Missing novelty in drug development. Rev. Financial Stud. 35(2):636–679.Crossref, Google Scholar
• Krieger JL, Li X, Thakor RT (2022b) Find and replace: R&D investment following the erosion of existing products. Management Sci. 68(9):6552–6571.Link, Google Scholar
• Ladanie A, Schmitt AM, Speich B, Naudet F, Agarwal A, Pereira TV, Sclafani F, et al. (2020) Clinical trial evidence supporting US Food and Drug Administration approval of novel cancer therapies between 2000 and 2016. JAMA Network Open 3(11):e2024406.Crossref, Google Scholar
• Laise E (2023) Incyte shares drop after FDA approves GSK’s competing blood-cancer treatment. MarketWatch (September 18), https://www.marketwatch.com/story/incyte-shares-drop-after-fda-approves-gsks-competing-blood-cancer-treatment-8fcc9490.Google Scholar
• Law MR, Kawasumi Y, Morgan SG (2011) Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov. Health Affairs 30(12):2338–2345.Crossref, Google Scholar
• Lendrem DW, Lendrem BC, Peck RW, Senn SJ, Day S, Isaacs JD (2015) Progression-seeking bias and rational optimism in research and development. Nature Rev. Drug Discovery 14(3):219–221.Crossref, Google Scholar
• Levin D, Peck J, Ye L (2009) Quality disclosure and competition. J. Indust. Econom. 57(1):167–196.Crossref, Google Scholar
• Lexchin J, Bero L, Djulbegovic B, Clark O (2008) Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ 326:1167–1170.Crossref, Google Scholar
• Lieberman MB (1987) Postentry investment and market structure in the chemical processing industries. RAND J. Econom. 18(4):533–549.Crossref, Google Scholar
• Lieberman MB, Montgomery DB (1988) First-mover advantages. Strategic Management J. 9(S1):41–58.Crossref, Google Scholar
• Lu ZJ, Comanor WS (1998) Strategic pricing of new pharmaceuticals. Rev. Econom. Statist. 80(1):108–118.Crossref, Google Scholar
• MacKinlay AC (1997) Event studies in economics and finance. J. Econom. Literature 35(1):13–39.Google Scholar
• Marandett E, Savage C (2021) Conducting clinical trials part 2: Avoiding mistaken public disclosures. Choate. Accessed October 8, 2024, https://www.choate.com/insights/conducting-clinical-trials-part-2-avoiding-mistaken-public-disclosures.html.Google Scholar
• Marinovic I, Varas F (2016) No news is good news: Voluntary disclosure in the face of litigation. RAND J. Econom. 47(4):822–856.Crossref, Google Scholar
• Markopoulos PM, Hosanagar K (2018) A model of product design and information disclosure investments. Management Sci. 64(2):739–759.Link, Google Scholar
• Markou P, Kavadias S, Oraiopoulos N (2023) Rival signals and project selection: Insights from the drug development process. Management Sci. 69(9):5298–5315.Link, Google Scholar
• Martin L, Hutchens M, Hawkins C, Radnov A (2017) How much do clinical trials cost. Nature Rev. Drug Discovery 16(6):381–382.Crossref, Google Scholar
• Masur J, Ouellette L (2023) Patent Law: Cases, Problems, and Materials. https://www.patentcasebook.org/.Google Scholar
• Matsa DA (2011) Competition and product quality in the supermarket industry. Quart. J. Econom. 126(3):1539–1591.Crossref, Google Scholar
• McCann BT, Vroom G (2010) Pricing response to entry and agglomeration effects. Strategic Management J. 31(3):284–305.Crossref, Google Scholar
• Mello MM, Francer JK, Wilenzick M, Teden P, Bierer BE, Barnes M (2013) Preparing for responsible sharing of clinical trial data. New England J. Med. 369(17):1651–1658.Google Scholar
• Mihm J, Sting FJ, Wang T (2015) On the effectiveness of patenting strategies in innovation races. Management Sci. 61(11):2662–2684.Link, Google Scholar
• Milgrom PR (1981) Good news and bad news: Representation theorems and applications. Bell J. Econom. 12:380–391.Crossref, Google Scholar
• Milgrom PR (2008) What the seller won’t tell you: Persuasion and disclosure in markets. J. Econom. Perspect. 22(2):115–131.Crossref, Google Scholar
• Miller KL (2017) Do investors value the FDA orphan drug designation? Orphanet J. Rare Diseases 12(1):1–6.Crossref, Google Scholar
• Mirowski P, Van Horn R (2005) The contract research organization and the commercialization of scientific research. Soc. Stud. Sci. 35(4):503–548.Crossref, Google Scholar
• Morton FMS (1999) Entry decisions in the generic pharmaceutical industry. RAND J. Econom. 30(3):421–440.Crossref, Google Scholar
• Morton FMS (2000) Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry. Internat. J. Indust. Organ. 18(7):1085–1104.Crossref, Google Scholar
• Mullard A (2023) The high, and redundant, cost of failure in cancer drug development. Nature Rev. Drug Discovery 22(9):688.Crossref, Google Scholar
• Myers K (2020) The elasticity of science. Amer. Econom. J. Appl. Econom. 12(4):103–134.Crossref, Google Scholar
• National Center for Science and Engineering Statistics and Census Bureau (2018) National Center for Science and Engineering Statistics and Census Bureau Business Research and Development Survey. Report, National Science Foundation, Alexandria, VA.Google Scholar
• Pagliarulo N (2023) Lilly market value soars on higher sales, obesity drug potential. Accessed January 8, 2024, https://www.biopharmadive.com/news/lilly-mounjaro-obesity-second-quarter-stock-value/690224/.Google Scholar
• Pfizer (2019) Pfizer’s commitment to the EFPIA/PhRMA data-sharing principles. Accessed February 10, 2024, https://cdn.pfizer.com/pfizercom/research/research_clinical_trials/Pfizer_EFPIA_PhRMA_commitments_022819.pdf.Google Scholar
• Pharmaceutical Research and Manufacturers of America (PhRMA) and European Federation of Pharmaceutical Industries and Associations (EFPIA) (2023) PhRMA-EFPIA principles for responsible clinical trial data sharing. Accessed October 8, 2024, https://www.efpia.eu/media/qndlfduy/phrmaefpiaprinciplesforresponsibledatasharing2023.pdf.Google Scholar
• Philippidis A (2023) StockWatch: Novo Nordisk shares soar as Ozempic aces phase III CKD trial. Accessed January 8, 2024, https://www.genengnews.com/topics/drug-discovery/stockwatch-novo-nordisk-shares-soar-as-ozempic-aces-phase-iii-ckd-trial/.Google Scholar
• Prager E, Schmitt M (2021) Employer consolidation and wages: Evidence from hospitals. Amer. Econom. Rev. 111(2):397–427.Crossref, Google Scholar
• Prayle A, Hurley M, Smyth A (2012) Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: Cross sectional study. BMJ 344:d7373.Crossref, Google Scholar
• Prince JT, Simon DH (2015) Do incumbents improve service quality in response to entry? Evidence from airlines’ on-time performance. Management Sci. 61(2):372–390.Link, Google Scholar
• Rao A (2022) Industry-funded research and bias in food science. Quant. Marketing Econom. 20(1):39–67.Crossref, Google Scholar
• Reinganum JF (1989) The timing of innovation: Research, development, and diffusion. Schmalensee R, Willig R, eds. Handbook of Industrial Organization, vol. 1 (Elsevier, Amsterdam), 849–908.Crossref, Google Scholar
• Seamans RC (2012) Fighting city hall: Entry deterrence and technology upgrades in cable TV markets. Management Sci. 58(3):461–475.Link, Google Scholar
• Seamans RC (2013) Threat of entry, asymmetric information, and pricing. Strategic Management J. 34(4):426–444.Crossref, Google Scholar
• Shaked A, Sutton J (1982) Relaxing price competition through product differentiation. Rev. Econom. Stud. 49(1):3–13.Crossref, Google Scholar
• Shapiro B (2018) Positive spillovers and free riding in advertising of prescription pharmaceuticals: The case of antidepressants. J. Political Econom. 126(1):381–437.Crossref, Google Scholar
• Shrank W, Rogstad T, Parekh N (2019) Waste in the US healthcare system. J. Amer. Medical Assoc. 322(15):1501–1509.Crossref, Google Scholar
• Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Cardiovascular risk associated with Celecoxib in a clinical trial for colorectal adenoma prevention. New England J. Medicine 352(11):1071–1080.Crossref, Google Scholar
• Sun L, Abraham S (2021) Estimating dynamic treatment effects in event studies with heterogeneous treatment effects. J. Econometrics 225(2):175–199.Crossref, Google Scholar
• Teece DJ (1986) Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy. Res. Policy 15(6):285–305.Crossref, Google Scholar
• Teece D, Pisano G (2003) The dynamic capabilities of firms. Holsapple CW, ed. Handbook on Knowledge Management, International Handbooks on Information Systems, vol. 2 (Springer, Berlin), 195–213.Crossref, Google Scholar
• Tirole J (1988) The Theory of Industrial Organization (MIT Press, Cambridge, MA).Google Scholar
• U.S. Food and Drug Administration (1998) Guidance for industry: FDA approval of new cancer treatment uses for marketed and biological products. Technical report, U.S. Food and Drug Administration, Washington, DC.Google Scholar
• U.S. Food and Drug Administration (2007) Food and Drug Administration Act of 2007 (2007) Public Law No. 110-185 §801. U.S. Food and Drug Administration, Washington, DC.Google Scholar
• U.S. Government Accountability Office (2020) FDA drug approval: Application review times largely reflect agency goals. U.S. Government Accountability Office, Washington, DC.Google Scholar
• Viscusi WK (1978) A note on “lemons” markets with quality certification. Bell J. Econom. 9(1):277–279.Crossref, Google Scholar
• Vonkeman HE, Brouwers JR, van de Laar MA (2006) Understanding the NSAID related risk of vascular events. BMJ 332(7546):895–898.Crossref, Google Scholar
• Wilson D (2011) Glaxo settles cases with US for $3 billion. New York Times (November 3), https://www.nytimes.com/2011/11/04/business/glaxo-to-pay-3-billion-in-avandia-settlement.html.Google Scholar
• Wittich CM, Burkle CM, Lanier WL (2012) Ten common questions (and their answers) about off-label drug use. Mayo Clinic Proc. 87(10):982–990.Crossref, Google Scholar
• Zarin D, Tse T (2008) Moving toward transparency of clinical trials. Science 319(5868):1340–1342.Crossref, Google Scholar
• Zarin DA, Tse T, Williams R, Carr S (2016) Trial reporting in ClinicalTrials.gov—The final rule. New England J. Medicine 375(20):1998–2004.Crossref, Google Scholar
• Zarin DA, Tse T, Williams R, Califf R, Ide NC (2011) The ClinicalTrials.gov results database—Update and key issues. New England J. Medicine 369(9):852–860.Crossref, Google Scholar